12 November 2025
\n \n \n \nThe Composition of Matter patent covers the Company\u2019s novel PGN-EDODM1 molecule and serves as a cornerstone of its expanding patent portfolio.
\n \n\n \n \n6 November 2025
\n \n \n \nGroundbreaking research using Nucleome MCC technology reveals complex structure of DNA inside\r\nliving cells at base pair resolution for the first time, pioneering a new approach to identify new drug\r\ntargets from human genetics.
\n \n\n \n \n4 November 2025
\n \n \n \nEnara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens\u00ae and the development of bispecific T cell engagers for solid tumours, will unveil its newly discovered cancer-specific target DARKFOX\u2122 as the first in a new category of validated Dark Antigens in an oral presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 annual meeting. SITC 2025 is being held on November 5-9 in National Harbor, MD.
\n \n\n \n \n31 October 2025
\n \n \n \nThe University of Liverpool rand CyanoCapture Ltd are joining forces to develop the next generation of carboxysome-based targeted drug delivery systems, exploiting unique traits found in fast-growing cyanobacteria.
\n \n\n \n \n30 October 2025
\n \n \n \nLeveraging deep scientific and clinical expertise in MPNs, the company aims to drive a pipeline of disease-modifying precision therapies that selectively target disease-driving cells. Progress is being made with AT-01, a first-in-class antibody-drug conjugate (ADC) program, which has strong preclinical validation and is advancing toward IND/CTA-enabling studies anticipated to start in the first half of 2026. Additionally, AT-02 expands the ADC portfolio by targeting mutant CALR, a key driver mutation in MPNs. The leadership and board have been strengthened with the appointments of Dr. Rohit Batta as CEO and Mike Grey as Chair.
\n \n\n \n \n27 October 2025
\n \n \n \nU-Ploid is today presenting its first scientific abstract, \u201cPreclinical testing of a novel therapeutic for reduction of aneuploidy in oocytes,\u201d at the 2025 American Society for Reproductive Medicine (ASRM) Annual Meeting in San Antonio, Texas. The study showcases preclinical data on Lyvanta\u2122 (UP-085), a novel therapeutic designed to reduce chromosome segregation errors in oocytes associated with maternal age.
\n \n\n \n \n23 October 2025
\n \n \n \nMediMabBio has successfully raised KRW 25.6B (USD $17M) in its Series B financing round. The newly secured capital will be used to expand strategic global partnerships for accelerated business development and the advancement of follow-on programs.
\n \n\n \n \n15 October 2025
\n \n \n \nWe are delighted to celebrate the graduation of Exogene as it transitions from the BioEscalator to its new home at the Wood Centre for Innovation.
\n \n\n \n \n14 October 2025
\n \n \n \nSimon brings over two decades of strategic leadership and investment expertise across diagnostics, biotech, and digital health innovation.
\n \n\n \n \n12 October 2025
\n \n \n \nMediMabBio won first place at Innovation Tiger 2025, a global biotech startup competition held at Shonan iPark in Japan. The final round featured 16 companies selected from 79 applicants across Korea, Japan, and Taiwan.
\n \n\n \n \n10 October 2025
\n \n \n \nDr. Peter Jianrui Liu, Co-Founder of OXcan, has decided to step down from his role as the Company\u2019s Founding CEO, to pursue other interests. He will remain a significant shareholder in the Company and therefore will retain every interest in the Company\u2019s development and success as an advisor.
\n \n\n \n \n8 October 2025
\n \n \n \nWe are delighted to welcome Professor Heidi Johansen-Berg to our Management Board, an expert in brain imaging and neuroplasticity, and a champion of innovation in the life sciences.
\n \n\n \n \n6 October 2025
\n \n \n \nDr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260. THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer.
\n \n\n \n \n23 September 2025
\n \n \n \n53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing. PGN-EDODM1 was generally well-tolerated at 15 mg/kg, with drug-related adverse events mild or moderate in severity
\n \n\n \n \n23 September 2025
\n \n \n \nPepGen currently intends to use the net proceeds from this offering to fund its ongoing research and clinical development efforts, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as for working capital and other general corporate purposes.
\n \n\n \n \n17 September 2025
\n \n \n \nFirst phase completed a year earlier than typical industry timelines
\n \n\n \n \n12 September 2025
\n \n \n \nIn the piece, CEO and co-founder Dr. Peter Jianrui Liu shares how the company is pioneering a non-invasive blood test for the early detection of lung cancer, using proteomics and AI/ML. Oxford Cancer Analytics' technology aims to change the way cancers are diagnosed, detecting disease earlier, cutting costs for health systems, and most importantly, saving lives.
\n \n\n \n \n10 September 2025
\n \n \n \nStay informed with the latest BioEscalator updates, tenant and alumni news in the Autumn 2025 edition of the BioEscalator Bulletin.
\n \n\n \n \n9 September 2025
\n \n \n \nWe are delighted to welcome Omos Biosciences as the newest member of the BioEscalator community. The company has ambitious plans to transform cancer prevention by intervening at the pre-cancerous stage.
\n \n\n \n \n8 September 2025
\n \n \n \nFollows successful completion of pre-clinical activities by Alchemab as part of an earlier licensing deal with Eli Lilly and Company for ATLX-1282. Financing included participation from Eli Lilly and Company and Ono Venture Investment alongside significant support from world-class existing investors.
\n \n\n \n \n